Top Page
Sigma Healthcare Ltd
(Sydney:SIG)
Sigma Healthcare Ltd (SIG) vs. iShares MSCI Australia ETF (EWA)
Sigma Healthcare Ltd Business Overview & Revenue Model
Sigma Healthcare Ltd Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.89B | 3.32B | 3.66B | 3.45B | 3.40B |
| Gross Profit | 334.05M | 189.82M | 224.07M | 199.42M | 210.61M |
| EBITDA | 55.47M | 53.25M | 50.20M | 30.23M | 68.96M |
| Net Income | -13.84M | 4.51M | 1.81M | -7.24M | 43.53M |
Balance Sheet | |||||
| Total Assets | 1.83B | 1.40B | 1.20B | 1.28B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 14.57M | 356.50M | 16.65M | 31.14M | 16.13M |
| Total Debt | 132.09M | 136.63M | 226.99M | 323.43M | 215.23M |
| Total Liabilities | 991.29M | 531.52M | 723.84M | 786.65M | 705.00M |
| Stockholders Equity | 837.86M | 870.77M | 475.92M | 487.19M | 513.67M |
Cash Flow | |||||
| Free Cash Flow | -323.50M | 37.25M | 113.34M | -60.48M | -64.56M |
| Operating Cash Flow | -315.59M | 41.97M | 142.74M | -46.28M | -13.13M |
| Investing Cash Flow | -1.60M | 5.73M | -28.60M | -16.59M | 124.36M |
| Financing Cash Flow | -24.73M | 295.82M | -116.94M | 128.89M | -265.71M |
Sigma Healthcare Ltd Technical Analysis
Sigma Healthcare Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% | |
47 Neutral | €33.88B | ― | -1.63% | 0.34% | 45.73% | -231.34% | |
| €322.11M | ― | -4.46% | ― | ― | ― | ||
| $5.42B | 1,144.55 | 0.52% | 2.00% | ― | ― | ||
73 Outperform | AU$12.83B | 23.44 | 6.86% | 3.29% | 10.15% | 6.20% | |
58 Neutral | AU$2.30B | 152.30 | -276.16% | 2.12% | 25.38% | ― | |
58 Neutral | AU$549.90M | 18.19 | 18.39% | 2.50% | 7.80% | 99.87% |
Sigma Healthcare Ltd Corporate Events
Sigma Healthcare Ltd has announced the appointment of PWC as its new auditor, effective from April 23, 2025, following approval from the Australian Securities & Investment Commission. This change comes after Sigma’s merger with the Chemist Warehouse Group, with PWC being chosen for their experience as the incumbent auditor for CWG. The transition marks a strategic move for Sigma, aligning its auditing services with its expanded operations post-merger. A resolution to ratify this appointment will be presented at Sigma’s 2025 Annual General Meeting.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has announced a significant change in the shareholding interests of its director, Danielle Di Pilla. Over the course of four days in May 2025, Di Pilla disposed of a substantial number of shares, reducing her direct holdings from 61,243,218 to 31,401,068 ordinary shares. This change, executed through on-market trades, reflects a strategic decision that may impact the company’s stock market presence and influence shareholder perceptions.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd’s Sustainability Report for 2024/25 highlights the company’s commitment to sustainability and its recent merger with Chemist Warehouse. This merger is expected to strengthen Sigma’s market position and enhance its value chain, benefiting customers and the community. The report outlines Sigma’s governance, environmental initiatives, and approach to sustainability, reflecting its dedication to responsible business practices.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its Corporate Governance Statement for the financial year ending January 31, 2025, which outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. The statement, which is available on the company’s website, confirms that Sigma Healthcare has followed the recommended governance practices, including board management roles and responsibilities, director appointment checks, and accountability of the company secretary. This release is significant as it underscores Sigma Healthcare’s commitment to transparency and robust governance, which is crucial for maintaining investor confidence and regulatory compliance.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its Corporate Governance Statement for 2024/25, highlighting its commitment to high standards of corporate governance and adherence to the ASX Corporate Governance Principles and Recommendations. Following its merger with Chemist Warehouse in February 2025, the company plans to review and update its corporate governance framework to align with the merged entity’s needs. The Board’s responsibilities include setting strategic goals, overseeing management, and ensuring risk management and legal compliance. The merger has also led to changes in the Board’s composition, with a mix of Executive and Non-Executive Directors.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd’s Annual Report for 2024/25 outlines the company’s financial performance, operational highlights, and strategic initiatives. The report provides insights into Sigma’s efforts to strengthen its market position through business acquisitions and enhanced financial management. It also highlights the company’s commitment to maintaining robust financial health and delivering value to its stakeholders.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its Annual Report and other related documents for the year ending January 31, 2025, reflecting its position before merging with the Chemist Warehouse Group. The merger, completed in February 2025, prompts a review of the company’s reporting practices to align with the new entity, highlighting a significant transition in Sigma’s operations and strategic direction.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has announced a change in the director’s interest, with Damien Gance, the director, disposing of 126,500,000 ordinary shares through an off-market trade. This transaction impacts the holdings of the DGSR Family Foundation Pty Ltd, which now holds 127,329,615 ordinary shares, reflecting a strategic adjustment in the director’s financial interests within the company.
The most recent analyst rating on (AU:SIG) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Limited announced a trading update following its merger with Chemist Warehouse Group, revealing a 36% growth in Normalised EBIT for the nine months ending March 31, 2025, consistent with Chemist Warehouse’s performance for the first half of FY25. The merger is treated as a reverse acquisition for accounting purposes, with Chemist Warehouse as the accounting acquirer, and Sigma’s financial results for FY25 will include Chemist Warehouse’s financials from the merger date. The announcement highlights significant transaction costs and the impact of inter-company sales on earnings.
Sigma Healthcare Ltd has announced a significant change in the director’s interest, with Damien Gance disposing of 100,000,000 ordinary shares through an off-market trade. This transaction reduces the holdings of the DGSR Family Foundation Pty Ltd, for which Gance is the sole director and shareholder, potentially impacting the company’s shareholder structure and market perception.